Orthofix, BAB Agree to Market, Distribute Bone Biomaterials

Orthofix International has entered into an agreement with Berkeley Advanced Biomaterials (BAB) wherein Orthofix will market and distribute an FDA-cleared line of bone repair resorbable biomaterials engineered by BAB for trauma and reconstruction applications.

Under the agreement, Orthofix will market and sell this line of BAB resorbable biomaterials that will be packaged for Orthofix as granules, blocks, moldable putty and putty-injection kits. This line of osteoconductive bone scaffold biomaterials based on nanocrystalline hydroxyapatite technology is engineered to resorb quickly, thereby allowing bone to remodel rapidly.

"This product line, which we will be branding as OsteoMax, gives Orthofix's nearly 500 company representatives and independent distributors another great reason to call on their orthopedic-surgeon customers -- providing them with an outstanding solution for filling bone voids related to trauma and reconstruction applications," said Charles Federico, Orthofix's group president and CEO.